Champions Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Champions Oncology's estimated annual revenue is currently $20.2M per year.
- Champions Oncology received $5.2M in venture funding in June 2016.
- Champions Oncology's estimated revenue per employee is $85,405
- Champions Oncology's total funding is $36.8M.
- Champions Oncology has 237 Employees.
- Champions Oncology grew their employee count by 14% last year.
Champions Oncology Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Champions Oncology?
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today's needs and innovating for tomorrow's challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company's Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient's tumor, enabling them to better select treatment regimens.keywords:Biotechnology,Enterprise Software,Health It,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
Champions Oncology News
Champions Oncology (US); The Jackson Laboratory (US); ONCODESIGN (France); Charles River Laboratories International (US); EPO Berlin-Buch GmBH (Germany)...
Crown Bioscience; Champions Oncology; Horizon Discovery; Hera Biolabs; Genoway; Vitalstar Biotechnology; Ingenious Targeting Laboratory; Axenis; Trans Genic...
Hackensack, NJ - October 20, 2021 - Champions Oncology (NASDAQ: CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned OpenZone Life Sciences Campus in Bresso, Italy, on the doorstep of Milan. After launching preclinical and clin ...
DGAP-News: Champions Oncology, Inc. / Key word(s): Miscellaneous Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus 20.10.2021 / 14:00 The issuer is solely responsible for the content of this announcement. Champions O ...
DGAP-News: Champions Oncology, Inc. / Key word(s): Strategic Company Decision Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development 26.07.2021 / 14:30 The issuer is solely responsible for the content of this announcement. HEADLINE: Champions On ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Champions Oncology Funding
|2015-03-13||$14.0M||Undisclosed||New Enterprise Associates||Article|
|2016-06-13||$5.2M||Undisclosed||National Securities Corporation||Article|